Poland-based AI drug development company Ingenix has raised €13 million in a seed extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.

The funding will support further development of the company’s Biological Reasoning Engine, an artificial intelligence platform designed to analyse and integrate biological data across multiple sources and scales. Ingenix said it will also use the investment to expand collaborations with pharmaceutical and biotechnology companies through its newly launched Qualified Access Program.

Founded in 2023, Ingenix is developing what it describes as a Modality Fusion architecture, which combines specialised AI models trained on different biological datasets rather than relying on a single large model. The company argues that biology’s complexity requires systems capable of reasoning across multiple data types, including biological, chemical and clinical information.

Piotr Surma, chief executive officer and co-founder of Ingenix, said: “This funding lets us extend the Biological Reasoning Engine to the partners and questions where it can do the most useful work.

“We built Ingenix on the conviction that biology needs an AI architecture designed for biology and not a general-purpose model retrofitted to it. The early results have been stronger than we forecast, and we’re excited to extend the Engine to a select number of partners through the Qualified Access Program.”

The financing comes amid growing investment in AI-enabled drug discovery platforms as pharmaceutical companies seek new ways to accelerate target identification, biomarker discovery and therapeutic development.

According to Ingenix, its platform is designed to support translational and clinical research and development decisions by analysing relationships across multiple biological datasets and generating hypotheses that researchers can investigate experimentally.

The company highlighted a recent collaboration with an oncology-focused biotechnology company involving antibody-drug conjugate (ADC) payload selection. Ingenix said its system was used to assess thousands of potential dual-payload ADC combinations and generated 15 candidate combinations for review.

According to the company, five of the proposed combinations aligned with publicly known hypotheses, two were supported by existing scientific literature, three matched findings previously generated internally by the biotech partner and five represented novel hypotheses. Ingenix said the partner identified three of those novel hypotheses as actionable candidates.

The company stated that the work was completed in minutes and claimed it replicated insights that had previously required several years of research and significant financial investment. These results have not been independently verified.

Simon Turner, partner at Sofinnova Partners, said: “It is no longer enough to just build models.

“Ingenix is building the reasoning layer, the part that actually connects the biology, the chemistry, and the clinical data into something a scientist can interrogate and act on. That’s the hard bit, and that’s where the value compounds. We’re thrilled to back a team that gets that.”

Sofinnova Partners, which focuses on life sciences and sustainability investments, manages more than €4 billion in assets. OTB Ventures is a European deep technology investor focused on artificial intelligence, advanced computing, robotics and space technologies.

Ingenix said applications are now open for its Qualified Access Program, which will provide selected pharmaceutical and biotechnology partners with access to the Biological Reasoning Engine.